Azacitidine in untreated acute myeloid leukemia: A report on 149 patients

American Journal of Hematology

Volumn 89, Issue 4, 2014, Pages 410-416

  Thépot, Sylvain ^a   Itzykson, Raphael ^a   Seegers, Valerie ^b   Recher, Christian ^c   Raffoux, Emmanuel ^d   Quesnel, Bruno ^e   Delaunay, Jacques ^f   Cluzeau, Thomas ^g   Marfaing Koka, Anne ^h   Stamatoullas, Aspasia ⁱ   Chaury, Marie Pierre ^j   Dartigeas, Caroline ^k   Cheze, Stéphane ^l   Banos, Anne ^m   Morel, Pierre ⁿ   Plantier, Isabelle ^o   Taksin, Anne Laure ^p   Marolleau, Jean Pierre ^q   Pautas, Cecile ^r   Thomas, Xavier ^s   Isnard, Francoise ^t   Beve, Blandine ^a   Chait, Yasmine ^u   Guerci, Agnes ^v   Vey, Norbert ^w   Dreyfus, Francois ^x   Ades, Lionel ^a   Ifrah, Norbert ^y   Dombret, Herve ^d   Fenaux, Pierre ^a   Gardin, Claude ^a   more..

^a UNIVERSITÉ PARIS 13   (France)

^b HÔTEL DIEU   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f NANTES UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF NICE   (France)

^h HÔPITAL ANTOINE BÉCLÈRE   (France)

ⁱ CENTRE HENRI BECQUEREL   (France)

^j LIMOGES UNIVERSITY HOSPITAL   (France)

^k UNIVERSITY HOSPITAL OF TOURS   (France)

^l CAEN UNIVERSITY HOSPITAL   (France)

^m CENTRE HOSPITALIER   (France)

ⁿ Centre Hospitalier de LENS   (France)

^o CENTRE HOSPITALIER DE ROUBAIX   (France)

^p LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^q AMIENS UNIVERSITY HOSPITAL   (France)

^r HENRI MONDOR HOSPITAL   (France)

^s UNIVERSITÉ DE LYON   (France)

^t ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^u Centre Hospitalier Intercommunal Le Raincy Montfermeil   (France)

^v UNIVERSITY HOSPITAL OF NANCY   (France)

^w INSTITUT PAOLI CALMETTES   (France)

^x NONE   (France)

^y ANGERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLEEDING; BONE MARROW; CANCER CHEMOTHERAPY; COMPASSIONATE USE; CONTROLLED STUDY; CYTOGENETICS; DRUG DOSE REDUCTION; DRUG FATALITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HOSPITAL READMISSION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SEPSIS; TREATMENT RESPONSE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; COHORT STUDIES; COMPASSIONATE USE TRIALS; FEBRILE NEUTROPENIA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; SEPSIS; TREATMENT OUTCOME;

EID: 84897387993     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23654     Document Type: Article

References (40)

1. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107:3481-3485.
2. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-474.
3. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007;25:1908-1915.
4. Prebet T, Boissel N, Reutenauer S, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: A collaborative study of the French CBF-AML intergroup. J Clin Oncol 2009;27:4747-4753.
5. Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: A Cancer and Leukemia Group B study. J Clin Oncol 2010;28:596-604.
6. Gardin C, Chevret S, Pautas C, et al. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. J Clin Oncol 2013;31:321-327.
7. Rao AV, Valk PJ, Metzeler KH, et al. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol 2009;27:5580-5586.
8. Frohling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: Results from AMLSG trial AML HD98-B. Blood 2006;108:3280-3288.
9. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 2009;10:223-232.
10. Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011;117:403-411.
11. Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011;29:1987-1996.
12. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24:3895-3903.
13. Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: The alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009;27:3842-3848.
14. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010;107:7473-7478.
15. Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007;25:3884-3891.
16. Cashen AF, Schiller GJ, O'Donnell MR, et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010;28:556-561.
17. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012;30:2670-2677.
18. Al-Ali HK, Jaekel N, Junghanss C, et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: A multicenter phase I/II study. Leuk Lymphoma 2012;53:110-117.
19. Lubbert M, Ruter BH, Claus R, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 2012;97:393-401.
20. Maurillo L, Venditti A, Spagnoli A, et al. Azacitidine for the treatment of patients with acute myeloid leukemia: Report of 82 patients enrolled in an Italian Compassionate Program. Cancer 2012;118:1014-1022.
21. Sudan N, Rossetti JM, Shadduck RK, et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer 2006;107:1839-1843.
22. An international system for human cytogenetic nomenclature (1978) ISCN (1978). Report of the Standing Commitee on Human Cytogenetic Nomenclature. Cytogenet Cell Genet 1978;21:309-409.
23. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-1320.
24. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813-819.
25. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-425.
26. Kaplan E, Meier P. Non parametric estimations from incomplete observations. J Amer Stat Assoc 1958;53:457-481.
27. Peto R, Peto J. Asymptotycally efficient rank invariant test procedures. J Stat Soc 1972;135:185-206.
28. Cox D. Regression models and life tables. J Roy Statist Soc Ser B 1972;34:187-220.
29. Raffoux E, Cras A, Recher C, et al. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 2010;1:34-42.
30. Pleyer L, Stauder R, Burgstaller S, et al. Azacitidine in patients with WHO-defined AML-Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. J Hematol Oncol 2013;6:32.
31. Quintas-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 2012;120:4840-4845.
32. Goodyear O, Agathanggelou A, Novitzky-Basso I, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010;116:1908-1918.
33. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007;110:2302-2308.
34. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28:562-569.
35. Silverman LR, Fenaux P, Mufti GJ, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011;117:2697-2702.
36. Kayser S, Doehner K, Krauter J, et al. Secondary AML after a history of myelodysplastic syndrome is an independent adverse prognostic factor for achievement of complete remission, relapse-free and overall survival. An analysis of 2, 819 adult patients with newly diagnosed AML enrolled on seven AMLSG Treatment Trials. ASH Annual Meeting Abstracts 2009;114:2621.
37. Gore SD, Fenaux P, Santini V, et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 2013;98:1067-1072.
38. Pollyea DA, Kohrt HE, Gallegos L, et al. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia 2012;26:893-901.
39. Metzeler KH, Walker A, Geyer S, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia 2012;26:1106-1107.
40. Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011;25:1147-1152.